Cancer Gene Therapy

Suicide Gene Therapy for Bile Duct Cancer Explored in Murine Model

Published in Cancer Weekly, July 21st, 1997

Herpes simplex virus type-1 thymidine kinase (HStk)/ganciclovir (GCV) suicide gene therapy successfully treated human bile duct cancer in a nude mouse model.

Complications of local tumor invasion, especially progressive bile duct stenosis, generally determine the morbidity and mortality in patients with bile duct cancer (BDC). Because the site of stenosis can be routinely accessed during stent placement, this suggests the possibility of achieving BDC tumor control by local gene therapy.

"As a first step, we have tested the effectiveness of systemic therapy with GCV on human bile duct carcinoma expressing the herpes simplex thymidine kinase (HStk)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-07-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry